CONMED (NYSE:CNMD) Issues FY 2025 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 4.480-4.530 for the period, compared to the consensus EPS estimate of 4.470. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

CONMED Stock Performance

NYSE:CNMD traded up $0.65 during trading hours on Friday, reaching $44.86. 190,654 shares of the stock were exchanged, compared to its average volume of 456,897. The stock has a market capitalization of $1.39 billion, a P/E ratio of 12.68, a P/E/G ratio of 1.59 and a beta of 1.15. The firm has a 50 day simple moving average of $48.44 and a 200-day simple moving average of $51.93. The company has a quick ratio of 1.00, a current ratio of 2.23 and a debt-to-equity ratio of 0.88. CONMED has a 52 week low of $41.62 and a 52 week high of $78.00.

CONMED (NYSE:CNMD) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. CONMED had a return on equity of 14.43% and a net margin of 8.31%.The business had revenue of $337.93 million for the quarter, compared to analyst estimates of $334.76 million. During the same period in the prior year, the company posted $1.05 EPS. The business’s revenue was up 6.7% compared to the same quarter last year. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. As a group, sell-side analysts forecast that CONMED will post 4.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Piper Sandler dropped their target price on CONMED from $68.00 to $55.00 and set an “overweight” rating on the stock in a research report on Thursday. Wells Fargo & Company dropped their price objective on shares of CONMED from $57.00 to $47.00 and set an “equal weight” rating on the stock in a report on Thursday. JPMorgan Chase & Co. cut their price objective on shares of CONMED from $58.00 to $52.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of CONMED in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $54.00.

Insider Buying and Selling

In other CONMED news, Director Charles Farkas sold 2,000 shares of the company’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $53.52, for a total value of $107,040.00. Following the completion of the sale, the director directly owned 14,859 shares of the company’s stock, valued at approximately $795,253.68. This represents a 11.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.10% of the company’s stock.

Institutional Trading of CONMED

Large investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP raised its position in CONMED by 490.3% during the second quarter. Engineers Gate Manager LP now owns 22,433 shares of the company’s stock valued at $1,168,000 after buying an additional 18,633 shares during the period. California State Teachers Retirement System grew its stake in shares of CONMED by 1.6% in the 2nd quarter. California State Teachers Retirement System now owns 28,522 shares of the company’s stock valued at $1,485,000 after buying an additional 442 shares in the last quarter. Qube Research & Technologies Ltd increased its holdings in CONMED by 56.2% in the second quarter. Qube Research & Technologies Ltd now owns 28,452 shares of the company’s stock worth $1,482,000 after buying an additional 10,233 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in CONMED during the second quarter valued at approximately $1,280,000. Finally, Intech Investment Management LLC lifted its stake in CONMED by 34.6% in the first quarter. Intech Investment Management LLC now owns 22,505 shares of the company’s stock valued at $1,359,000 after acquiring an additional 5,780 shares during the last quarter.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.